Impala Nordic comments on OncoZenge AB (publ) (“OncoZenge” or the “Company”) latest news, including the appointment of Dr. Marie-Louise Fjällskog as Chief Medical Officer (CMO) and the positive one-month initial stability results for the BupiZenge™ technology batch.

The initial stability results, reported within specifications, provide an early indication that the cross-partner manufacturing set-up is functioning as intended, lowering the risk of late manufacturing-related setbacks as the program progresses toward full GMP production. In parallel, Dr. Fjällskog, an oncologist and Associate Professor at Uppsala University, strengthens clinical leadership as the program moves into execution. We also note that while short-term liquidity has been supported via the bridge from Linc AB, the delayed tranche 3 payment from strategic investor Sichuan Yangtian Bio-Pharmaceutical Co. Ltd raises added focus on funding confidence around the remaining tranche payment.

Read the full comment here.

For additional information, please contact:

Charlie Dahlström, Equity Research Analystcharlie@impalanordic.se

About Impala Nordic

Impala Nordic provides company analysis, coverage, and comprehensive investor relations (IR) services. The portfolio includes listed small-cap companies, where Impala Nordic acts as a communicative bridge between the companies and investors.

The material produced by Impala Nordic is independent but sponsored. This means that Impala Nordic has received payment from the client to produce the analysis and coverage. The client has not been able to influence Impala Nordic’s opinions expressed in the material.